FORM 3
 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden hours per response... 0.5

(Print or Type Responses)
1. Name and Address of Reporting Person *
  BHONSLE SUNIL
 2. Date of Event Requiring Statement (Month/Day/Year)
03/15/2010		 3. Issuer Name and Ticker or Trading Symbol
TITAN PHARMACEUTICALS INC [TTNP:PK]
(Last)
(First)
(Middle)
400 OYSTER POINT BLVD., SUITE 505		 4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
__X__ Director _____ 10% Owner
__X__ Officer (give title below) _____ Other (specify below)
President
 5. If Amendment, Date Original Filed(Month/Day/Year)
(Street)

SO. SAN FRANCISCO, CA 94080		 6. Individual or Joint/Group Filing(Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
(City)
(State)
(Zip)
Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security
(Instr. 4)		 2. Amount of Securities Beneficially Owned
(Instr. 4)		 3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5)		 4. Nature of Indirect Beneficial Ownership
(Instr. 5)
Common Stock, $0.001 par value per share 65,500 (1)
D
 
Common Stock, $0.001 par value per share 225,757
I
By Family Trust (2)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. SEC 1473 (7-02)
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 4)		 2. Date Exercisable and Expiration Date
(Month/Day/Year)		 3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4)		 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5)		 6. Nature of Indirect Beneficial Ownership
(Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Option to Purchase Common Stock 01/08/2001 01/08/2011 Common Stock 42,000 $ 22.98 D  
Option to Purchase Common Stock 08/09/2001 08/09/2011 Common Stock 31,500 $ 11.63 D  
Option to Purchase Common Stock 01/16/2002 01/16/2012 Common Stock 90,000 $ 8.77 D  
Option to Purchase Common Stock 03/01/2003 03/01/2013 Common Stock 50,000 $ 1.5 D  
Option to Purchase Common Stock 02/09/2004 02/09/2014 Common Stock 60,000 $ 3.69 D  
Option to Purchase Common Stock 02/07/2005 02/07/2015 Common Stock 70,000 $ 2.62 D  
Option to Purchase Common Stock 01/03/2006 01/03/2016 Common Stock 80,137 $ 1.4 D  
Option to Purchase Common Stock 08/29/2006 08/29/2016 Common Stock 11,250 $ 2.35 D  
Option to Purchase Common Stock 01/03/2007 01/03/2017 Common Stock 76,666 $ 3.13 D  
Option to Purchase Common Stock 05/30/2008 05/30/2018 Common Stock 5,000 $ 1.52 D  
Option to Purchase Common Stock 05/17/2009 05/17/2019 Common Stock 100,000 $ 0.79 D  
Option to Purchase Common Stock   (3) 05/17/2019 Common Stock 700,000 $ 0.79 D  
Option to Purchase Common Stock   (4) 05/17/2019 Common Stock 10,000 $ 0.79 D  

Reporting Owners

Reporting Owner Name / Address Relationships
Director 10% Owner Officer Other
BHONSLE SUNIL
400 OYSTER POINT BLVD., SUITE 505
SO. SAN FRANCISCO, CA 94080		   X     President  

Signatures

/s/ Sunil Bhonsle 03/15/2010
**Signature of Reporting Person Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 5(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1) Does not include 10,000 shares of common stock beneficially owned by the reporting person's adult son.
(2) The reporting person is the trustee of a family trust owning the indicated shares.
(3) 175,000 options were fully vested on May 17, 2009 with the balance of the options vesting in 48 equal monthly installments beginning on May 17, 2009 with the vesting of 100,000 shares contingent upon the sale or partnering of Titan Pharmaceuticals, Inc.'s Probuphine program.
(4) These options vest in 12 equal monthly installments beginning on May 17, 2009.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.